Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06999733 · ClinicalTrials.gov registry record · Phase 1

A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophic Keratitis

A Phase 1 study of Neurotrophic Keratitis, sponsored by Krystal Biotech.

Recruiting
Registry status
Phase 1
Development phase
60
Enrollment target
9
Study locations

NCT06999733 is a Phase 1 study of Neurotrophic Keratitis that is actively recruiting participants, run by Krystal Biotech. The registered enrollment target is 60 participants, above the 14-participant average among 6 other Neurotrophic Keratitis trials with a reported enrollment target (329% higher). The trial reports 9 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06999733, a Phase 1 study of Neurotrophic Keratitis, is actively recruiting participants, sponsored by Krystal Biotech.

RECRUITING
Registry status
Phase 1
Development phase
60 participants
Enrollment target
9
Study locations

Study Summary

The Sponsor is developing KB801, a replication-defective, non-integrating herpes simplex virus type 1 (HSV-1)-derived vector engineered to deliver functional full-length human nerve growth factor (NGF) to the corneas of people with Stage 2 or 3 neurotrophic keratitis (NK) via topical application. This is a Phase 1/2, multicenter, double-masked, placebo-controlled study to evaluate the safety, tolerability, and preliminary efficacy of KB801 in these subjects.

Conditions Studied

Neurotrophic Keratitis

Interventions

  • DRUG Placebo
  • BIOLOGICAL KB801

Study Locations (9)

California

  • UC Irvine Alpha Clinic - Irvine
  • Azul Vision - California Eye Specialists Medical Group Inc. - Pasadena

Minnesota

  • Vance Thompson Vision - Alexandria
  • Minnesota Eye Consultants - Minnetonka

Indiana

  • Midwest Cornea Associates - Carmel

Missouri

  • St. Louis Eye Institute - Town and Country

New Jersey

  • Metropolitan Eye Research and Surgery Institute - Palisades Park

North Dakota

  • Vance Thompson Vision - West Fargo

Pennsylvania

  • UPMC Vision Institute - Pittsburgh

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2025-07-07
Est. Completion 2027-12
Phase Phase 1

Sponsor

Krystal Biotech

13 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06999733

The ClinicalTrials.gov registry entry for NCT06999733 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 14-participant average among 6 other Neurotrophic Keratitis trials with a reported enrollment target (329% higher). The listed sponsor is Krystal Biotech, which has 13 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Neurotrophic Keratitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06999733 reports 9 study locations spanning 7 distinct geographic areas - top geographies include California, Minnesota, Indiana.

Frequently Asked Questions

What is clinical trial NCT06999733 about?

NCT06999733 is a clinical study titled "A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophic Keratitis". The Sponsor is developing KB801, a replication-defective, non-integrating herpes simplex virus type 1 (HSV-1)-derived vector engineered to deliver functional full-length human nerve growth factor (NGF) to the corneas of people with Stage 2 or 3 neurotrophic keratitis (NK) via topical application. Th...

What is the current status of trial NCT06999733?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2025-07-07. Estimated completion is 2027-12.

What conditions does trial NCT06999733 study?

This clinical trial studies the following conditions: Neurotrophic Keratitis.

What interventions are being tested in trial NCT06999733?

The interventions under investigation include: Placebo (DRUG), KB801 (BIOLOGICAL).

Who is sponsoring clinical trial NCT06999733?

This trial is sponsored by Krystal Biotech, which has 13 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06999733 being conducted?

This trial has 9 study locations across California, Indiana, Minnesota, Missouri, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Neurotrophic Keratitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Neurotrophic Keratitis

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.